source
- Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacySanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
- US judge upholds law to curb hospital drug prices as shortage trends show mixed signalsA federal judge in Washington rejected a pharmaceutical industry challenge to a state law aimed at lowering hospital drug prices, leaving the pricing reforms in place. Data from a recent analysis…